VBI Vaccines

VBI Vaccines Employees

9 people indexed:

Adam Buckley

Senior Vice President, Business Development

73323f08@73h17qhzthj.d8t Sign up to see email

8d8q3z9p@h4wwz2j6769.624 Sign up to see email
Athena Kartsaklis

Senior Vice President, Finance

7pu0yjppwuq@63zzzddh745.pzz Sign up to see email

76ujfw93dyh@uujz4w917u2.x77 Sign up to see email
Avi Mazaltov

Global Head of Manufacturing and SciVac General Manager

3yyd87x13@k3fj30w7x4f.1g7 Sign up to see email

r70ywp030@jw4h9dpd05q.5x0 Sign up to see email
David E. Anderson

Chief Scientific Officer

7z.2kf52wxf@wufulq41q5l.px9 Sign up to see email

8w.jpftph2u@f06k78w7xl1.055 Sign up to see email
Francisco Diaz-Mitoma

Chief Medical Officer

j8gp68lu7y65@u3r9w0xgq5k.ujp Sign up to see email

u3l76u5q65y4@k7wyjgh1wqr.488 Sign up to see email
Jeff Baxter

President and CEO

1ku0l3h@y6qzf8k6500.5wp Sign up to see email

p3d371w@yhq23h1hf78.kp6 Sign up to see email
John Dillman

Chief Commercial Officer

59pkhf00@p28t27uw57t.4kw Sign up to see email

0tq1h2wu@gp68w54135z.1r2 Sign up to see email
Misha Nossov

Senior Vice President, Global Commercial Supply Strategy & Head of Europe

591ygkf@5ftrk6f7u3p.gtx Sign up to see email

2fh7rh0@hjk6664lf73.004 Sign up to see email
Nell Beattie

Chief Financial Officer and Head of Corporate Development

7ufyukr7@3yld1zlr22y.gp3 Sign up to see email

hk0z407u@2f7fup9yf4w.j8j Sign up to see email

VBI Vaccines Company Information

VBI Vaccines, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the development of vaccine candidates that mimic the natural presentation of viruses to harness the innate power of the human immune system. The company targets significant infectious diseases such as hepatitis B, COVID-19, other coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers like glioblastoma (GBM). VBI Vaccines operates research facilities in Ottawa, Canada, and has a research and manufacturing site in Rehovot, Israel. The company’s innovative approach includes the use of virus-like particles (VLPs), featuring proprietary technologies such as the enveloped VLP (eVLP) platform and a proprietary mRNA-launched eVLP (MLE) platform.

Report inaccurate information